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SOD1 is a cause of the fatal, paralytic disorder ALS. Although mechanisms underlying mutant SOD1 neuro-
toxicity remain uncertain, this protein associates with mitochondria. In this issue of Neuron, Israelson et al.
show that mutant SOD1 binds and inhibits the mitochondrial channel VDAC1. This finding sheds light onto
possible molecular links between mutant SOD1, mitochondrial dysfunction, and spinal motor neuron degen-
eration in inherited ALS.Amyotrophic lateral sclerosis (ALS) is
a rapidly progressive paralytic disorder
of middle and late life characterized
mainly by a loss of cortical motor neurons
and lower motor neurons in the brainstem
and spinal cord (Pasinelli and Brown,
2006). There is no apparent genetic
linkage in about 90% of ALS patients,
but in the remaining cases, the disease
is inherited (Pasinelli and Brown, 2006).
Among the individuals with familial ALS,
roughly one-fifth map to chromosome
21, where there are mutations in the
gene for the antioxidant enzyme super-
oxide dismutase 1 (SOD1) (Pasinelli and
Brown, 2006). In transgenic mice carrying
the SOD1G85R mutation, overexpression
of wild-type SOD1 failed to modify the
expression of the disease (Bruijn et al.,
1998), supporting the notion that the
mutated allele gives rise to a gain-of-func-
tion phenotype. Although in vitro studies
indicate that mutant SOD1 exerts its dele-
terious effects via a combination of cell-
autonomous and non-cell-autonomous
processes, as illustrated in Nagai et al.
(2007), the actual nature of the acquired
adverse property remains to be estab-
lished. Relevant to this outstanding issue,
Israelson and collaborators have now
performed a comprehensive set of inves-
tigations in the mutant SOD1 model of
ALS from which has emerged, as shown
in this issue of Neuron, an exciting and
novel hypothesis: a mitochondrial chan-
nelopathy underpins neurodegeneration
in this disease.
SOD1 is known to be essentially a cyto-
solic enzyme, but a portion of mutant
SOD1, especially when overexpressed,has been identified in mitochondria
(Pasinelli and Brown, 2006). This physical
association has led researchers to posit
that mislocalized mutant SOD1, by
affecting mitochondrial functions, may
contribute to the degeneration of motor
neurons in this familial form of ALS. Con-
sistent with this view, reduced respiratory
chain activity, abnormally high release of
apoptogenic mitochondrial molecules
such as cytochrome c, and impairedmito-
chondrial movement have all been docu-
mented in transgenic mice expressing
mutant SOD1 (Kirkinezos et al., 2005;
Magrane et al., 2009; Pasinelli and Brown,
2006).
One way that mislocalized mutant
SOD1 could impact on mitochondrial
biology is through aberrant interactions
with essential proteins associated with
this organelle. For example, mutant
SOD1 has already been shown to bind to
Bcl-2 (Pasinelli et al., 2004) and lysyl-
tRNA synthetase (Kawamata et al.,
2008). Now, Israelson et al. (2010) report
the remarkable finding that mutant SOD1
also interacts with the mitochondrial
voltage-dependent anion channel-1
(VDAC1/porin-1). They found that VDAC1
(but not its related homolog VDAC2) coim-
munoprecipitates with the catalytically
active SOD1G93A and inactive SOD1H46R
mutants but not with the wild-type SOD1
protein in solubilized mitochondrial
lysates from rat spinal cords. Surprisingly,
no evidence of an interaction between
VDAC1 and mutant SOD1 is detected in
protein extracts prepared from brain
tissues despite the fact that the latter
contains copious amounts of mutantNeuron 67SOD1 protein. The authors suggest that
this regional specificitymight beexplained
by the higher content of the known VDAC1
interactor, hexokinase-1 (Azoulay-Zohar
et al., 2004), in brain compared to spinal
cord, which may outcompete mutant
SOD1. Yet, to support this proposal, addi-
tional experiments are still needed. For
example, this proposal would be strength-
ened by (1) immunocytochemical studies
showing that ALS-resistant ocular motor
neurons express more hexokinase-1 than
ALS-susceptible spinal motor neurons
and (2) in vitro competition experiments
showing that addition of hexokinase-1
recombinant attenuates the magnitude of
SOD1/VDAC1 interaction.
By using an antibody that binds to a
disease-specific epitope inaccessible on
correctly folded SOD1, the authors were
able to demonstrate that the VDAC1/
SOD1 interaction involves, at least in
part, misfolded SOD1 protein, which may
represent the actual toxic species. Mis-
folded SOD1 protein—and consequently
its interaction with VDAC1—is detected
only in spinal cord mitochondrial fractions
of transgenicmutantSOD1 ratsandonly in
symptomatic animals. These results
suggest that the binding of the noxious
misfolded SOD1 conformer to VDAC1
parallels the time course of the disease
and is restricted to areas most affected
in this ALS animal model.
Next, to examine the potential func-
tional significance of the VDAC1/SOD1
interaction, Israelson et al. (2010) mea-
sured ion channel conductance of purified
VDAC1 reconstituted into a planar lipid
bilayer by voltage clamp, as before, August 26, 2010 ª2010 Elsevier Inc. 523
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that mutant SOD1 proteins (SOD1G93A
and SOD1G85R), but not the wild-type
SOD1 protein, reduce the ion conductivity
of VDAC1. To assess another important
function of VDAC1, but this time in a more
genuine setting, the authors assessed the
uptake of ADP by mitochondria isolated
from spinal cords of transgenic SOD1G93A
rats. This experiment showed a reduced
ADP accumulation in mitochondria from
presymptomatic animals and, even more
so, from symptomatic animals. Collec-
tively, these functional data suggest that,
in the presence of mutant SOD1, VDAC1
is partially closed, a conformational state
thought, at least by some, to adversely
impact on normal mitochondrial functions
(Mannella and Kinnally, 2008). Of note,
high concentrations of the hexokinase
reaction product glucose 6-phosphate
can reopen VDAC1 (Azoulay-Zohar et al.,
2004). Thus, should mutant SOD1-medi-
ated VDAC1 closure be deleterious and
should glucose 6-phosphate be able to
alleviate the effect of mutant SOD1 on
VDAC1 conductance, this small molecule
may have to be considered as a potential
neuroprotective compound for the treat-
ment of ALS.
In the last part of their study, Israelson
et al. (2010) wanted to determine the
in vivo significance of a loss of VDAC1
conductance on the ALS phenotype by
crossing transgenic SOD1G37R mice with
mutant mice carrying one or two VDAC1
null alleles. The outcome of this experi-
ment is striking, in that SOD1G37R/
VDAC1–/– mice reached end-stage paral-
ysis 16% sooner than their SOD1G37R/
VDAC1+/+ counterparts. However, if the
mutant SOD1/VDAC1 interaction were
pathogenically important in SOD1-linked
ALS, one would predict that abrogation524 Neuron 67, August 26, 2010 ª2010 Elsevof VDAC1 should have instead extended
lifespan of animals. However, in the
absence of histological data, whether
the shortened lifespan in transgenic
SOD1G37Rmicedeficient inVDAC1reflects
a true exacerbation of the neurodegenera-
tive process or is just a confound due to
functional abnormalities in cardiac and
skeletal muscles (Anflous et al., 2001)
cannot be sorted out.
Although the work of Israelson et al.
(2010) opens a compelling new way of
thinking about the neurobiology of ALS,
at this point, it seems that the jury is still
out as to whether the loss of channel
conductance plays a pathogenic role in
this inherited form of ALS. VDAC1 plays
a key role in mitochondrial-dependent
apoptosis (Mannella and Kinnally, 2008),
a form of cell death that is thought to drive
the ultimate demise of motor neurons in
ALS (Gue´gan and Przedborski, 2003)
and in mitochondrial turnover by autoph-
agy (Geisler et al., 2010). Furthermore,
VDAC1 is a major component of mito-
chondria-associated endoplasmic retic-
ulum (ER) membranes (MAM); these are
zones of physical interaction between
mitochondria and the ER. Interestingly,
the MAM has pivotal roles in a host of
cellular functions, including Ca2+ sig-
naling, lipid transport, energy metabo-
lism, and cellular survival (Hayashi et al.,
2009), and, in addition to mitochondria,
mutant SOD1 also localizes to the ER
(Kikuchi et al., 2006). Therefore, whether
mutant SOD1-associated VDAC1 alter-
ations promote neurodegeneration here
through inhibition of channel conduc-
tance or one of these alterative VDAC1
functions, or a combination of both, may
have to be considered in future studies
designed to bring closure to this channel-
opathy story.ier Inc.REFERENCES
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